Project Grant R35HL184177
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Columbia University's Health Sciences Division a $1,394,592 Project Grant (CFDA 93.837: Cardiovascular Diseases Research) effective August 5, 2025, with completion targeted for March 31, 2026. This research project investigates epitranscriptomic regulation mechanisms in hematopoietic stem cell (HSC) niche generation and regeneration within the bone marrow. The award supports basic and...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $166,644 to The Trustees of Columbia University in the City of New York (Health Sciences Division) on July 16, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports research investigating inflammatory responses in human hematopoietic stem cells (HSCs) with a focus on understanding how aging and clonal hematopoiesis—specifically TET2 mutations—alter...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Columbia University's Health Sciences Division a $1,151,500 Project Grant on March 9, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct comprehensive research investigating macrophage biology in atherosclerosis and cardiometabolic disease through February 28, 2033. The research program will deliver mechanistic and translational findings addressing critical gaps in...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1.34 million Project Grant to Columbia University's Health Sciences Division on May 1, 2025, to support research under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds a seven-year research initiative (through April 30, 2032) titled "Finding and Pushing the Limits of Macrophage Efferocytosis in Atherosclerosis." The research aims to develop novel therapeutic targets...
- Federal Grant Award Summary Weill Medical College of Cornell University received a $802,301 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective June 10, 2025, with completion targeted for April 30, 2029. This research initiative, titled "Controlling the Niche to Control Clonal Hematopoiesis," will deliver scientific research services focused on understanding and developing therapeutic...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Weill Medical College of Cornell University a $109,076 Project Grant (CFDA 93.837 – Cardiovascular Diseases Research) on March 3, 2026, with a completion date of September 14, 2029. The project, titled "Expanding Single-Cell Transcriptomics to Chart the Role of Noncoding RNAs in Normal Hematopoiesis," will deliver computational and experimental research services to advance understanding of how...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Icahn School of Medicine at Mount Sinai a Project Grant of $1,175,924 under the Cardiovascular Diseases Research program (CFDA 93.837) effective April 1, 2026, with an ultimate completion date of January 31, 2033. This research grant supports Dr. Sturgeon's investigation into hemogenic mesoderm heterogeneity, regulation, and function—specifically examining the molecular and transcriptional mechanisms by...
- Federal Project Grant Award Summary Fred Hutchinson Cancer Center received a $776,511 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, with completion targeted for May 31, 2029. This award supports research to develop and validate a three-dimensional engineered hemogenic vascular niche model designed to elucidate the microenvironmental factors that promote hematopoietic stem...
- Federal Project Grant Award Summary The University of Southern California received a $198,164 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 24, 2025, with completion targeted for March 31, 2029. The research investigates heterogeneous intercellular signaling patterns among hematopoietic stem and progenitor cells (HSPCs) and how circadian rhythms modulate these signaling...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Columbia University a $729,703 Project Grant on July 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and optimize cell sorting technology for stem cell therapy applications. The research focuses on developing "nanovials," an innovative platform designed to isolate and enrich mesenchymal stem cells (MSCs) based on their extracellular vesicle (EV)...
The National Heart, Lung, and Blood Institute (NHLBI) awarded Columbia University's Health Sciences Division a $1.14 million Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) beginning April 1, 2026, with completion targeted for January 31, 2033. This award supports fundamental research investigating the dynamics and plasticity of the hematopoietic stem cell (HSC) niche—the specialized microenvironment that regulates blood cell production. The research will employ advanced methodologies including single-cell transcriptomics, imaging, metabolic analysis, and functional studies using novel mouse models to elucidate how niche cells dynamically regulate hematopoiesis during development, regeneration, and hematological disease states. The project deliverables encompass mechanistic discoveries regarding niche cell dynamics and fate plasticity, identification of key regulatory pathways controlling HSC function, and development of evidence-based approaches to enhance niche function and boost blood cell production. This research addresses a critical gap in understanding how the bone marrow and developing liver niches adapt to changing physiological demands, with broad implications for therapeutic intervention in regenerative medicine and hematological pathologies. The research will be conducted at Columbia University's facilities in New York, NY.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.1m | 3/31/26 |